PA4 preferentially targets hematological cancers. (A) Box plots of CAMKIIγ T287 phosphorylation/total protein level among 9 types of cancers from the cProSite database; ∗∗P < .01. (B) Summary of IC50 of BBM or PA4 in cancer-derived cell lines treated with BBM or PA4 for 72 hours. Data are shown as individual values with median. (C) Summary of IC50 of BBM or PA4 in 10 selected cell lines treated with PA4 for 72 hours. (D) Relative viability of H9 and human peripheral blood mononuclear cells (PBMCs) incubated with indicated dosages of PA4 for 24 hours. (E) CAMKIIγ T287 phosphorylation level among 10 selected cell lines from panel C was measured by western blot. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as loading control. Avg, average; CNS, central nervous system; HNC, head and neck cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; NSCLC, non–small cell lung cancer; PDAC, pancreatic adenocarcinoma; RLU, relative light unit.
